NCT04638634View on ClinicalTrials.gov

Pharmacokinetics, Safety, and Tolerability of CSL760, an Intravenous Anti-SARS-CoV-2 Hyperimmune Globulin, in Healthy Adult Subjects

PHASE1TerminatedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

February 2, 2021

Primary Completion Date

June 9, 2021

Study Completion Date

June 9, 2021

Conditions
Coronavirus Disease 2019 (COVID-19)
Interventions
BIOLOGICAL

CSL760

An Intravenous Anti-SARS-CoV-2 Hyperimmune Globulin

Trial Locations (1)

SA 5000

CMAX Clinical Research, Adelaide

Sponsors

Lead Sponsor

CSL Behring
All Listed Sponsors
lead

CSL Behring

INDUSTRY